ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Marla C. Dubinsky  ¹     Geert R. D'Haens  ²     William Sandborn  ³     Siew C. Ng  ⁴     Julian Panés  ⁵     Chinyu Su  ⁶     Nervin Lawendy  ⁶     Irina Lazariciu  ⁷     Sean Gardiner  ⁷     Rajiv Mundayat  ⁷     nicole kulisek  ⁷     Irene Modesto  ⁷     Joana Torres  ^8    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Amsterdam University Medical Centres, Amsterdam, Netherlands
³ University of California San Diego, La Jolla, United States
⁴ LKS Institute of Health Science, Chinese University of Hong Kong, Institute of Digestive Disease, Hong Kong, Hong Kong
⁵ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁶ Pfizer Inc, Collegeville, United States
⁷ Pfizer Inc, New York, United States
⁸ Hospital Beatriz Ângelo, Loures and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)